International Journal of Drug Delivery Technology
Volume 15, Issue 1

Formulation and Development of Sustained Release Tablets of Losartan Potassium using Chitosan as Rate Retarding Polymer 

Chaitali Kulkarni1*, Saurabh Mundada2, Pawan Meshram3, Madhuri Desai4 

1Dept of Pharmaceutical Chemistry, Shree Santkrupa College of Pharmacy Ghogaon, Karad, MH,India

2Department Quality assurance, Raosaheb Patil Danve College of Pharmacy, Badnapur, Jalna, Maharashtra, 431202, India

3University Institute of Chemical Technology, Kavayitri Bahinabai Chaudhari North Maharashtra University, Jalgaon, 425001, India

4Department of Pharmaceutics, KVV, Krishna Institute of Pharmacy, Karad, MH, India 

Received: 5th Jan, 2025; Revised: 12th Feb, 2025; Accepted: 25th Feb, 2025; Available Online: 25th Mar, 2025

ABSTRACT

This study aims to develop and evaluate the SR tablets  of Losartan Potassium (LP) using chitosan as rate retarding polymer. The tablets were developed by direct compression technique with varying concentration of chitosan at constat HPMC K100M concentration. The granules were characterised for various micromeritics characteristics followed by compression of tablets. The compressed tablets were characterised for physico chemical  properties. The CI values for the lubricated blend ranged from 7.35% (F3) to 14.97% (F5). These values suggest that all formulations exhibit good to fair flow properties, with F3 showing the best flow characteristics (CI = 7.35%). The HR values of the lubricated blends varied between 1.079 (F3) and 1.176 (F5), indicating acceptable to good flowability across all formulations. All tablet batches showed acceptable physical properties. Content uniformity was well maintained across batches, with values ranging from 97.25% to 100.29%. The lowest friability was observed in F3 (0.35%), suggesting superior tablet robustness. The pure LP was found to be released 100% within 1 hour time period. F1 exhibited the highest dissolution, with 100% drug release at 24 hours, while F5 shows the slowest release, reaching only 52% at the same time point. The stability study of losartan potassium (LP) sustained-release (SR) tablets under accelerated conditions over six months indicates minimal variations in critical quality attributes, demonstrating good stability. This study underscores the potential of chitosan-based SR formulations for enhancing therapeutic efficacy in hypertension management.

Keywords: Losartan, Sustained drug delivery, Shorter Half-life, tablets

How to cite this article: Chaitali Kulkarni, Saurabh Mundada, Pawan Meshram, Madhuri Desai. Formulation and Development of Sustained Release Tablets of Losartan Potassium using Chitosan as Rate Retarding Polymer International Journal of Drug Delivery Technology. 2025;15(1):261-65. doi: 10.25258/ijddt.15.1.36

References

  1. Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure: contemporary update. JACC: Heart Failure. 2017 Aug;5(8):543-51.
  2. Przezak A, Bielka W, Pawlik A. Hypertension and type 2 diabetes—the novel treatment possibilities. International journal of molecular sciences. 2022 Jun 10;23(12):6500.
  3. AlQahtani AD, O’Connor D, Domling A, Goda SK. Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment. Biomedicine & Pharmacotherapy. 2019 May 1;113:108750.
  4. Al-Hashimi N, Begg N, Alany RG, Hassanin H, Elshaer A. Oral modified release multiple-unit particulate systems: compressed pellets, microparticles and nanoparticles. Pharmaceutics. 2018 Oct 4;10(4):176.
  5. Van Nguyen H, Lee BJ. Dual release and molecular mechanism of bilayered aceclofenac tablet using polymer mixture. International journal of pharmaceutics. 2016 Dec 30;515(1-2):233-44.
  6. Andrade C. The practical importance of half-life in psychopharmacology. The Journal of Clinical Psychiatry. 2022 Jul 25;83(4):41940.
  7. Santi DV, Schneider EL, Reid R, Robinson L, Ashley GW. Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates. Proceedings of the National Academy of Sciences. 2012 Apr 17;109(16):6211
  8. Safdar R, Omar AA, Arunagiri A, Regupathi I, Thanabalan M. Potential of Chitosan and its derivatives for controlled drug release applications–A review. Journal of drug delivery science and technology. 2019 Feb 1;49:642-59.
  9. Lakio S, Tajarobi P, Wikström H, Fransson M, Arnehed J, Ervasti T, Simonaho SP, Ketolainen J, Folestad S, Abrahmsén-Alami S. Achieving a robust drug release from extended release tablets using an integrated continuous mixing and direct compression line. International Journal of Pharmaceutics. 2016 Sep 10;511(1):659-68.
  10. Paul S, Sun CC. Systematic evaluation of common lubricants for optimal use in tablet formulation. European Journal of Pharmaceutical Sciences. 2018 May 30;117:118-27.
  11. Ramu S, Kumar YA, Rao DS, Ramakrishna G. Formulation and evaluation of Valsartan oral dispersible tablets by direct compression method. American Journal of Advanced Drug Delivery. 2014;2(6):719-33.
  12. Tian B, Hua S, Tian Y, Liu J. Chemical and physical chitosan hydrogels as prospective carriers for drug delivery: A review. Journal of Materials Chemistry B. 2020;8(44):10050-64.
  13. Mikušová V, Mikuš P. Advances in chitosan-based nanoparticles for drug delivery. International journal of molecular sciences. 2021 Sep 6;22(17):9652.